Creates provisions relating to insurance coverage of alternatives to opioid drugs
Summary
HB 1680 creates a new section in Missouri insurance law requiring health benefit plans to cover nonopioid medications prescribed for acute pain on terms that are not less favorable than opioid alternatives. When a licensed health care professional prescribes a nonopioid drug for acute pain, the plan may not deny coverage in favor of an opioid, require the patient to first try an opioid, or impose higher cost-sharing on the nonopioid medication.
The bill defines key terms such as acute pain, enrollee, health benefit plan, and health care professional by reference to existing insurance statutes. Its protections would apply to health benefit plans delivered, issued, continued, or renewed on or after January 1, 2027. In practical terms, the bill is intended to reduce insurance barriers to nonopioid pain treatment and encourage use of alternatives to opioid medications.
Impact
The bill would amend Chapter 376, RSMo, by adding section 376.1280 and would regulate health benefit plan coverage decisions for acute-pain prescriptions. It would prohibit insurers from using step therapy or cost-sharing practices that favor opioids over nonopioid medications, thereby affecting insurers, health plans, enrollees, and prescribing providers in Missouri. The law would not mandate a specific drug, but it would require parity in coverage treatment for nonopioid prescriptions when prescribed for acute pain.
Sentiment
The available record shows no committee transcript or vote history, so there is no documented debate or recorded opposition in the provided materials. Based on the bill text and caption, the measure appears to be framed as a patient-access and opioid-alternatives bill, which typically suggests support for reducing opioid exposure and expanding treatment options. However, without hearing or vote data, the overall sentiment cannot be measured beyond the bill’s stated purpose.
Contention
The main policy issue is whether insurers should be prohibited from favoring opioids through coverage design, step therapy, or higher cost-sharing for nonopioid alternatives. Supporters would likely emphasize patient access, safer pain management, and opioid-sparing treatment, while potential critics could focus on insurer cost controls, formulary management, and the administrative impact of mandated parity. No specific stakeholder positions are documented in the provided context.